Belite Bio, Inc stock is up 7.05% since 30 days ago. The next earnings date is Aug 9, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 1 December’s closed higher than November. 100% of analysts rate it a buy.
Belite Bio, Inc engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue.